Cancer - Prostate(구연) Oral Session 1 / Cancer - Prostate (Ⅰ) (O-005) Grand Ballroom(2F) 11월28일(수) 13:00-14:00 전립선암 환자에서 생식선자극호르몬분비호르본길항제의 사용이 알츠하이머병과 파긴슨병의 발생에 미치는 영향: 전국환자를 대상으로 한 코호트 연구 한림대학교 의과대학 비뇨의학과교실¹,성균관대학교 의과대학 비뇨의학과교실²,울산대학교 의과대학 비뇨의학과교실³,한림대학교 의과대학 작업환경의학과교실⁴ 심명선¹,방우진¹,오철영¹,이용성¹,전성수²,안한종³,주영수⁴,조진선¹ Introduction: Recent studies have associated the use of androgen deprivation therapy (ADT) with Alzheimer’s (ALZ) and Parkinson’s disease (PKD) in patients with prostate cancer (Pca). We aimed to determine whether use of gonadotropin-releasing hormone agonist (GnRHa) increases the risk of those diseases. Materials and Methods: Using the National Insurance Service Database, we conducted an observational study of 579,377 men who sought treatment due to Pca between January 1, 2012 and December 31, 2016. After excluding patients with previously diagnosed ALZ, PKD and Chemotherapy, we extracted data of 3,198 patients who started GnRHa (GnRHa use) and 4,092 men who were newly diagnosed as Pca (Nonuse) from July 1, 2012 to December 31, 2012, with follow-up though December 31, 2016. Primary outcomes were development of ALZ and PKD. We also observed the association of ADT duration with the outcomes. Results: Mean age of patients with GnRHa use and nonuse were 73.13 ± 8.14 and 67.10 ± 9.12, respectively (p<0.0001). Compared with nonuse, GnRHa use demonstrated an increased incidence of ALZ (p=0.0193) while PKD did not show associations in the univariate analysis. However in the multivariate analysis, GnRHa use was not associated with an increased risk of ALZ (adjusted hazard ratio, 0.926; 95% CI, 0.780 to 1.099). The cumulative duration of ADT was also not associated with the outcomes. Conclusion: Our complete enumeration for Korean Pca population suggest that ADT was not associated with and increased risk of ALZ and PKD. Patients’ age should be carefully considered for the analysis in this subject. keywords : androgen deprivation therapy, prostate cancer, Alzheimer's disease, Parkinson's disease